Login to Your Account

Intrexon moves to expand gene delivery platform with Genvec buy

By Michael Fitzhugh
Staff Writer

Tuesday, January 24, 2017

An adenoviral gene delivery technology developed by Genvec Inc. has drawn active synthetic biology player Intrexon Corp. to acquire the company in a stock exchange Intrexon valued at about $7 per share, or about $19.4 million.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription